A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00131326
Recruitment Status : Completed
First Posted : August 18, 2005
Last Update Posted : July 31, 2017
Information provided by:

Brief Summary:
This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Hip Musculoskeletal Diseases Device: Synvisc (hylan G-F 20) Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : November 2003
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Primary Outcome Measures :
  1. Pain relief

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with symptomatic osteoarthritis pain of hip

Exclusion Criteria:

  • Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00131326

  Hide Study Locations
United States, Alabama
Alabama Clinical Therapeutics
Birmingham, Alabama, United States, 35235
John Higginbotham, MD Sports Medicine
Huntsville, Alabama, United States, 35802
United States, Arizona
Affiliated Orthopedic Specialists
Scottsdale, Arizona, United States, 85260
United States, Arkansas
Arkansas Orthopaedic Specialists
Little Rock, Arkansas, United States, 72205
United States, California
Cedars-Sinai Orthopedic Center
Los Angeles, California, United States, 90048
Jackson Arthritis Center
Oakland, California, United States, 94609
Orthopedic Medical Group
San Diego, California, United States, 92123
United States, Florida
Orthopedic Specialists of Tamp Bay, P.A.
Clearwater, Florida, United States, 33756
Orthopedic Institute at Mercy Hospital
Miami, Florida, United States, 33133
United States, Georgia
Hughston Sports Medicine Foundation
Columbus, Georgia, United States, 31909
United States, Idaho
Idaho Arthritis & Osteoporosis Center
Meridian, Idaho, United States, 83642
United States, Illinois
Northwestern Orthopaedic Institute
Chicago, Illinois, United States, 60611
Illinois Bone and Joint Institute, Ltd.
Morton Grove, Illinois, United States, 60053
United States, Iowa
David S. Tearse, MD (Private Practice)
Cedar Rapids, Iowa, United States, 52403
United States, Kansas
Kansas City Orthopedic Institute
Leawood, Kansas, United States, 66211
United States, Kentucky
Bluegrass Orthopaedics
Lexington, Kentucky, United States, 40509
United States, Louisiana
Orthopedic Specialists of Louisiana
Shreveport, Louisiana, United States, 71101
United States, Maryland
Maryland General Hospital
Baltimore, Maryland, United States, 21201
United States, Michigan
Family Orthopedic Associates
Flint, Michigan, United States, 48507
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New Jersey
UMDNJ-RWJ University Orthopedic Group
New Brunswick, New Jersey, United States, 08901
United States, New York
Hospital for Special Surgery
New York, New York, United States, 10021
United States, Oklahoma
Health Research Institute
Oklahoma City, Oklahoma, United States, 73109
United States, Oregon
Orthopedic Center for Joint Replacement & Sports Medicine
Grants Pass, Oregon, United States, 97527
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Lancaster Orthopedic Group
Lancaster, Pennsylvania, United States, 17601
Allegheny Orthopedic Associates
Pittsburgh, Pennsylvania, United States, 15212
United States, South Carolina
Conway Medical Center
Conway, South Carolina, United States, 29526
United States, Tennessee
Chattanooga Center for Sports
Chattanooga, Tennessee, United States, 37404
United States, Texas
Gurdev Gill, MD (Private Practice)
Lubbock, Texas, United States, 79410
United States, Virginia
Carilion Bone and Joint Center, Vinton Orthopedic Surgery
Vinton, Virginia, United States, 24179
United States, Washington
Arthritis Northwest
Seattle, Washington, United States, 98166-2967
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company

Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00131326     History of Changes
Other Study ID Numbers: SYNV-004-02
First Posted: August 18, 2005    Key Record Dates
Last Update Posted: July 31, 2017
Last Verified: July 2017

Keywords provided by Sanofi:
osteoarthritis of the hip
Musculoskeletal Diseases

Additional relevant MeSH terms:
Musculoskeletal Diseases
Osteoarthritis, Hip
Joint Diseases
Rheumatic Diseases
Protective Agents
Physiological Effects of Drugs